CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 184 filers reported holding CLOVIS ONCOLOGY INC in Q2 2015. The put-call ratio across all filers is 1.20 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $8,870,000 | -17.4% | 168,000 | +6.3% | 1.35% | +6.8% |
Q4 2017 | $10,744,000 | -17.5% | 158,000 | 0.0% | 1.26% | -32.1% |
Q3 2017 | $13,019,000 | +49.5% | 158,000 | +69.9% | 1.86% | +25.6% |
Q2 2017 | $8,708,000 | +217.3% | 93,000 | -53.5% | 1.48% | +107.7% |
Q2 2016 | $2,744,000 | +51.3% | 200,000 | +111.6% | 0.71% | +81.2% |
Q1 2016 | $1,814,000 | -45.2% | 94,500 | 0.0% | 0.39% | -18.8% |
Q4 2015 | $3,308,000 | -65.7% | 94,500 | -10.0% | 0.48% | -60.7% |
Q3 2015 | $9,656,000 | -8.4% | 105,000 | -12.5% | 1.23% | +19.3% |
Q2 2015 | $10,546,000 | +26.3% | 120,000 | +6.7% | 1.03% | +18.9% |
Q1 2015 | $8,348,000 | +81.9% | 112,455 | +37.2% | 0.87% | +11.1% |
Q4 2014 | $4,589,000 | -0.8% | 81,955 | -19.6% | 0.78% | +37.0% |
Q3 2014 | $4,625,000 | +6.4% | 101,955 | -2.9% | 0.57% | -46.7% |
Q2 2014 | $4,348,000 | +56.9% | 105,000 | +162.5% | 1.07% | +69.4% |
Q1 2014 | $2,771,000 | +2.2% | 40,000 | -11.1% | 0.63% | -16.2% |
Q4 2013 | $2,712,000 | – | 45,000 | – | 0.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $18,097,419,000 | 17.62% |
Boxer Capital, LLC | 850,000 | $37,757,000 | 14.60% |
Consonance Capital Management LP | 2,730,887 | $121,306,000 | 13.32% |
Palo Alto Investors LP | 3,804,088 | $168,978,000 | 9.64% |
BLUE JAY CAPITAL MANAGEMENT, LLC | 298,982 | $13,281,000 | 8.01% |
Redmile Group, LLC | 1,620,355 | $71,976,000 | 6.20% |
Crosspoint Capital Strategies, LLC | 84,076 | $3,735,000 | 3.32% |
Ghost Tree Capital, LLC | 220,000 | $9,772,000 | 2.35% |
PointState Capital LP | 3,171,978 | $140,899,000 | 2.03% |
NEA Management Company, LLC | 1,139,890 | $50,634,000 | 2.01% |